Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%...
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was...
WAYNE, N.J., June 20, 2025 /PRNewswire/ -- CONSTANT MEDIA LLC, a leader in Point of Care (POC) marketing and provider...
This Fourth of July, Dr. Harbpinder Shevchenko, DMD of Smiles of Salem is going beyond red, white, and blue decorations—she's...
SEAFORD, Del., June 20, 2025 /PRNewswire/ -- Acclaimed physician, entrepreneur, and visionary healthcare leader Nihar Gala proudly announces two significant milestones...
Toronto, Ontario--(Newsfile Corp. - June 20, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce...
NEW YORK, June 20, 2025 /PRNewswire/ -- Players such as GE HealthCare, Siemens Healthineers, Philips, and Canon Medical are investing...
PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today announced a strategic partnership that...
PITTSBURGH, June 20, 2025 /PRNewswire/ -- Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, has announced...
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- Equity Insider News Commentary...
SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare...
LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a...
Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase...
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing...
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected...
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine...
Chicago physician and entrepreneur Dr. Anosh Ahmed expands long-term community initiatives focused on healthcare, education, and economic relief through the...
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone”...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared...
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal...